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of liposomal doxorubicin
David Fajardo-Ortiz1, Luis Duran2, Laura Moreno2, Hector Ochoa3 and Victor M Castaño4,5*Abstract
We explored how the knowledge translation and innovation processes are structured when theyresult in innovations,
as in the case of liposomal doxorubicin research. In order to map the processes, a literature network analysis was made
through Cytoscape and semantic analysis was performed by GOPubmed which is based in the controlled vocabularies
MeSH (Medical Subject Headings) and GO (Gene Ontology). We found clusters related to different stages of the
technological development (invention, innovation and imitation) and the knowledge translation process (preclinical,
translational and clinical research), and we were able to map the historic emergence of Doxil as a paradigmatic
nanodrug. This research could be a powerful methodological tool for decision-making and innovation management
in drug delivery research.
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Technological Innovation (TI) -the processes leading to
the emergence of new technologies in the market- and
Knowledge Translation (KT), −the conversion of research
results into better practices- notoriously converge, more
obvious than in any other scientific discipline, in bio-
medical sciences. The epistemological fundamental idea
behind both concepts is that Science must serve, prim-
ordially, to enhance the life conditions of Humankind.
Ever since the Enlightenment, modern history of human
society cannot be understood without that powerful
dream -Science helping to build a better world-, which
has been repeated over and over again by scientists and
philosophers, from Thomas Jefferson to Bertrand Russell
[1,2]. Regardless the specific epistemological approach to
Science, the transition from research results to the deliv-
ery of solutions to solve the needs of human society is the
common base of innovation and knowledge translation.
However, both processes are based on two very different
tautologies: KT is founded on a Medical and Health* Correspondence: meneses@unam.mx
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article, unless otherwise stated.sciences, with the moral obligation to provide useful
advice to build a better general health status [3], whereas
TI aims to produce temporal monopolies in a competitive
market context [4]. KT, therefore, is an effort to articulate
basic research with clinical practice and health social
goals and, to that effect, there is a continuing complaint
about science and practices being, in practice, poorly
communicated, i.e., that “we are lost in translation” [5].
In this regard, the United States government [6], as well
as other countries [7], have made important, and costly,
efforts to institutionalize strategies in order to accelerate
KT. Additionally, models [8] and experiences [9] on how
to close the gap between research and practices can be
found more and more frequently in the specialized
literature.
Accordingly, for the purposes of this article, TI process is
understood as the entire process of technological change.
TI process is composed by three phases: invention,
innovation and imitation. Invention is the stage in which
the technological base is created. Innovation starts when
the final inventions are published and ends when the
product is approved and delivered to the market. Imita-
tion is the research and development of the international
community following the success of the innovation leader
[10]. In turn, KT is divided in three steps: first, when basicentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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when the latter is translated to clinical practice and finally,
when these results in public health outcome [11].
It has been pointed out by various authors that there is
a disproportion between the number of papers published
and the amount of nanodrugs readily available in the
market [10]. Indeed, there exist thousands of papers as
compared to just 247 confirmed commercial products
in a preclinical, clinical or commercial stage [12]. The
question then arises on how TI is structured when a
nanodrug is approved, that is, when an innovation truly
emerges. The approach we offer herein to answer that
question consists in mapping the aforementioned pro-
cesses in the scientific literature network for a case
example, namely liposomal doxorubicin. Liposomes are
micro- and nano-scaled lipid bilayered “bubbles” that
can be used in a plethora of therapeutic strategies. The
therapeutic use of liposomes ranges from drug carriers
and drug delivery systems to multiplex with antibodies,
optical contrast, genetic material and others [13]. Liposo-
mal doxorubicin was chosen as an illustrative case study,
with a historical relevance, since a PEGylated liposomal
doxorubicin, Doxil, was the first nanodrug approved by
the United States Food and Drug Administration (FDA) in
1995 [14]. The proposed approach aims to understand
how scientific research evolves and gets re-organized
when a technological change process is taking place.
Moreover, this approach is aimed to provide insight
towards building more effective innovation policies in
health-oriented nanotechnologies.
This paper is based on a strong methodological and
exploratory approach. In this research, we identified the
concurrence of the TI and KT stages in the literature
network of liposomal doxorubicin research. The knowledge
translation pipeline in nanomedicine is a time-consuming
and complex road that requires acceleration [15]. This
methodology could be useful for the development of an
innovation roadmap for nanomedicine. This mapping
strategy could inform about which research groups, ideas
or approaches are effectively connecting the basic research
with the clinical observation [16,7]. Moreover, we have
shown, in a previous research, how this methodology
could provide accurate information about the current
status of development of a nanomedicine research. For
example, we have previously reported that two different
types of cancer nanotechnologies (liposomes or metallic
nanoparticles) are, actually, in two different stages of KT
and TI [17].
Accordingly, three different research strategies have
been developed to analyze KT in literature networks.
The first consists of classifying the papers either as dis-
covery (of risk factor associated with disease) or delivery
(of the interventions) research and identifying the key
cross-citation between these research fields [18,19]. Thesecond strategy consists in classifying the entire journals
as basic research, clinical research, clinical mix or clinical
observation, according the distribution of terms occurring
in the titles of the articles published in each journal. The
journals inter-citations are then analyzed [20,21]. Finally,
we have developed an innovative methodology [16,17]
which combines semantic analysis with network analysis
to identify hidden colleges and/or stages of the innovation
process. This methodology is based on the semantic
analysis performed by GOPUMED [22], which is based
in controlled vocabularies (Medical Subject Heading
[23] and Gene Ontology [24]).
Material and methods
A search of research papers on liposomal doxorubicin
(TITLE: (liposom*) AND TOPIC:(doxorubicin); Time-
span =All years; Indexes = SCI-EXPANDED, SSCI, A&HCI,
CPCI-S, CPCI-SSH) was made in the Web of Science
(WoS) [25] as for February 2014.
Twenty percent of the most cited papers were selected.
The distribution of citations in the scientific literature
follows a power law [26] i.e., there are few papers with a
huge quantity of citations and there are thousands of
manuscripts with few or no citations. Therefore, it is
meaningless to speak about representative samples. More-
over, power laws could be simplified with a 20/80 rule, i.e.,
20% of papers receive 80% of the citations [27]. When we
consulted the WoS for this particular field (liposomes and
doxorubicin) we found that this rule is fairly close to what
it is reported: 20% of the most cited papers received 83%
of the citations. Therefore, we reasonably chose the 20%
of the most cited papers because this quantity is large
enough to get most of the communication process that
happen in the literature network.
The software packages, Hiscite [28] and Pajek [29], were
used to build the citation network model. Cytoscape [30]
software was used to visualize and analyze the network
model. Clust&See [31], a Cytoscape plug-in, was used to
identify clusters (Tfit algorithm: modularity criterion,
multilevel transfer optimization), which could be related
to different stages on KT evolution or invisible colleges.
The Clust&See algorithms are based on the optimization
of Newman’s modularity [31]. This approach define clus-
ters as “groups of vertices within which connections are
dense but between which they are sparse” [32]. Therefore,
this algorithms put together papers that have the same
citation (connection) profile. In addition, Clust&See repre-
sented each found cluster as a single meta-node with a
size width is proportional to the number of their constitu-
ent nodes. Similarly, the meta-nodes are connected by
meta-edges, whose width is proportional to the number of
interactions among their vertices.
The papers of the network model were searched in the
engine GOPubMed [22], which semantically analyzed
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Subject Heading (MeSH) and Gene Ontology (GO). We
calculated the rate of clinical terms vs. non-clinical, since
we had previously defined as clinical terms all MeSH
terms belonging to the next higher hierarchy categories:
“Diagnosis”, “Therapeutics”, “Surgical Procedures, Opera-
tive”, “Named Groups”, “Persons” and “Health Care”.
The most central papers of each cluster (by higher
hierarchy and effective degree) were identified. Literature
networks constitute a particular type of genealogical
graphs [28,29], i.e., they are unidirectional networks in
which the papers have ancestors and/or descendants.
The paper with the highest hierarchy is the common
ancestor of the most of manuscripts in a cluster (sub-
network). Effective (weighted) degree is a measure of
centrality. This measure is calculated by counting the
effective number of edge weights connected to the given
node [33], i.e. how much a node is connected to the
most connected nodes.
We labeled the nodes (papers) of the network model
with the name of the institution and the country of the
correspondence author. In addition, we identify the main
institutions of each cluster by their number of papers.
This information could be useful to understand the rele-
vance of the international collaboration for the liposomal
doxorubicin innovation process.
The network model layout was displayed using the
“spring embedded” algorithm of Cytoscape [30]. Where
nodes act like particles that repels each others and con-
nections that act as springs. The resulting layout (with the
minimal sum of force in the network) puts together the
papers that tend to cite the same documents and separates
the papers that differ in their citing profile. The nodes
were colored according a continuous scale (from red to
blue), which is a function of the clinical terms rate.Results
1,747 papers related to liposomal doxorubicin were found
in WoS. 20% of those documents (350) were selected to
build the network model. These 350 papers received
30,360 citations (without counting auto-citations), which
represents 83% of the total citations received by the 1,747
documents found. This overwhelming percentage of cita-
tions provides a clue on the importance of this 20% of the
documents to the scientific communication on liposomal
doxorubicin through the literature network.
342 of these papers form one single citation weak net-
work, i.e., a network of papers connected for a least one
citation. We made sure that the each document are
labeled by GOPUBMED with the MeSH terms “doxo-
rubicin” and “liposome”, and discarded the papers that
did not have these terms. Finally, a literature network of
274 papers was obtained (Figure 1).Through the citation patrons of the network, Clust&see
identified 8 clusters of highly interconnected papers
(nodes) with the Tfit algorithm (Figure 1). After the
identification of the cluster, we performed an analysis of
the distribution of MesH and Go terms for each cluster.
This distribution suggests that clusters correspond to
different stages of TI and KT processes. Cluster 1 is
conformed by basic research papers and it is related to a
invention stage. Cluster 4 is basic research whereas
cluster 2 papers are clinical researches, both clusters
constitute the innovation stage, and the communication
between them represents the knowledge translation
process. Cluster 3 and 5 papers are basic researches and
they represent a sort of incremental innovation of lipo-
somal doxorubicin technology. Finally, Cluster 6, 7 and
8 are clinical observation researches aimed to extend
the usage of this nanodrug to others types of cancer
(Figure 1 and Tables 1 and 2).
Clusters are next described in a chronological order,
according to the average year of publication of their
papers. We identified the clusters by their size rank
(number of documents).
Cluster 1, the oldest, is a subnetwork of 61 papers
published between 1981 and 2009, being 1994 the aver-
age year. Most of papers of cluster 1 correspond to basic
research. The average rate of clinical terms is 0.09, i.e.,
the papers of this cluster correspond to basic research.
MeSH and Go terms are common to the others clusters,
i.e., there is no specialization in this subnetwork. The
papers with more effective degree and more centrality
values are about liposome size, drug charging, and low-
ering the cardiotoxicity (Table 2). The basic research
profile of this cluster, the average publishing year, its low
density, the topics of the most central papers, and the
non-specialized terms distributions suggest that cluster 1
is related to invention stage of liposomal doxorubicin.
Clusters 4 and 2, the next in the chronological order,
are built by 35 and 57 documents, respectively. The clus-
ter 4 papers were published between 1991 and 2009, and
1997 is the average year. Cluster 2 papers were published
between 1994 and 2007, with 2000 being the average year.
Clusters 4 and 2 have the strongest interconnectivity
through 149 citations (Figure 2). Both clusters share the
distinctive MeSH terms “Terapeutics” and “Drug carriers”
but the cluster 4 papers includes animal research (mice),
and cluster 2 is focused on patient treatment (Table 1).
The clinical terms rate of cluster 4 is 0.11 which indicates
that the papers are mostly basic research. Since the rate
for cluster 2 is 0.278, these papers trend to be translational
clinical research. The most central papers (by hierarchy
and effective degree) of both clusters are about Doxil, i.e.,
PEGylated liposomal doxorubicin (Table 2). All of above
suggests the TI process and KT take place in the inter-
action between clusters 2 and 4.
Figure 1 Mapping innovation and knowledge translation process on liposomal doxorubicin. The figure shows a network of inter-citations,
where the nodes are research papers on liposomal doxorubicins, which belong to 20% of the most cited articles in the field. The vertices of the
network are the citations between them. The form of the nodes is dependent on the cluster they belong to. The network names are given by
the GO or MeSH terms that distinguish them from the others.
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(Figure 1), and the average years are 2001 and 2003,
respectively. Both clusters correspond to basic research.
The corresponding MeSH and GO terms for cluster 3
are “Cells” and “cell” (Table 1). The central papers of
cluster 3 are about targeting the cancerous cells (Table 2).
Cluster 5 distinctive MeSH term is “temperature” (Table 1).
The central papers of cluster 5 are about hyperthermia
as an anti-cancer therapy (Table 2). The features of clusters
3 and 5 suggest that both constitute a sort of creative
bifurcation of the main innovation timeline of liposomal
doxorubicin, aimed to improve or to amplify its thera-
peutic performance.Finally, clusters 6, 7, and 8 are small groups of clinical ob-
servation papers, with an average rate of clinical terms of
0.36, 0.39 and 0.41, respectively. The three cluster are exten-
sions of cluster 2 (Figure 1 and 2). These clusters are related
to a imitation phase which attempts to improve the effi-
ciency, combine with other treatments, and extend the Doxil
application to different types of cancer (Tables 1 and 2).
Finally, the correspondence information of each paper
(Figure 1 and Table 3) shows that the leading research
institutions in liposomal doxorubicin are mainly located
in the United States, Canada, and Israel. The leading
institution along the innovation history of the liposomal
doxorubicin is the Hadassah Medical Organization (Israel).
Table 1 Top MeSh and GO terms associated with papers
belonging to each of the eight clusters
MeSH and GO terms Papers labeled with the term
Cluster 1
Doxorubicin 58
Liposomes 58
Pharmaceutical preparations 45
Animals 38
Neoplasms 32
Cluster 2
Doxorubicin 57
Liposomes 57
Humans 50
Patients 44
Female 44
Neoplasms 41
Adult 35
Middle aged 35
Therapeutics 30
Aged 29
Drug carriers 29
Cluster 3
Liposomes 50
Doxorubicin 48
Cells 40
cell 40
Animals 38
Pharmaceutical preparations 37
Mice 36
Humans 35
Neoplasms 31
Cluster 4
Liposomes 33
Doxorubicin 30
Pharmaceutical preparations 30
Neoplasms 27
Animals 27
Therapeutics 24
Drug Carriers 22
Mice 22
Humans 19
Cluster 5
Doxorubicin 34
Liposomes 34
Pharmaceutical preparations 28
Animals 25
Neoplasms 25
Temperature 18
Table 1 Top MeSh and GO terms associated with papers
belonging to each of the eight clusters (Continued)
Cluster 6
Doxorubicin 16
Humans 16
Liposomes 15
Patients 14
Male 14
Middle aged 12
Aged 12
Female 12
Treatment outcome 11
Polyethylene glycols 9
Therapeutics 9
Adult 9
Cluster 7
Doxorubicin 10
Liposomes 10
Patients 9
Humans 9
Female 8
Breast neoplasms 8
Survival 7
Neoplasms 7
Therapeutics 7
Aged 7
Adult 6
Middle aged 6
Safety 6
Cluster 8
Doxorubicin 9
Liposomes 9
Patients 9
Recurrence 9
Survival 9
Adult 9
Aged 9
Female 9
Humans 9
Middle aged 9
Ovarian neoplasms 9
Platinum 8
Polyethylene glycols 8
Disease-free survival 7
Neoplasms 7
Safety 6
Aged, 80 and over 6
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Table 2 Manuscripts with the highest degree of hierarchy within each of the clusters
Position Authors Citation Title
Cluster 1
The first by degree Mayer, L D, Tai, L C, Ko, D S, Masin, D,
Ginsberg, R S, Cullis, P R, Bally, M B
Cancer research (Cancer Res), Vol. 49
(21): 5922–30, 1989
Influe of vesicle size, lipid composition,
and d -to-lipid ratio on the biological
activi f liposomal doxorubicin in mice.
Second by degree Mayer, L D, Tai, L C, Bally, M B, Mitilenes,
G N, Ginsberg, R S, Cullis, P R
Biochimica et biophysica acta (Biochim
Biophys Acta), Vol. 1025 (2): 143–51, 1990
Chara rization of liposomal systems
conta g doxorubicin entrapped in
respo to pH gradients.
Second by degree Herman, E H, Rahman, A, Ferrans, V J,
Vick, J A, Schein, P S
Cancer research (Cancer Res), Vol. 43
(11): 5427–32, 1983
Preve n of chronic doxorubicin cardiotoxicity
in be s by liposomal encapsulation.
The first by hierarchy Forssen, E A, Tökès, Z A Proceedings of the National Academy of
Sciences of the United States of America
(P Natl Acad Sci Usa), Vol. 78 (3): 1873–7, 1981
Use o ionic liposomes for the reduction of
chron oxorubicin-induced cardiotoxicity.
Cluster 2
The first by degree Muggia, F M, Hainsworth, J D, Jeffers, S, Miller,
P, Groshen, S, Tan, M, Roman, L, Uziely, B,
Muderspach, L, Garcia, A, Burnett, A, Greco,
F A, Morrow, C P, Paradiso, L J, Liang, L J .
Journal of clinical oncology: official journal
of the American Society of Clinical Oncology
(J Clin Oncol), Vol. 15 (3): 987–93, 1997
Phase tudy of liposomal doxorubicin in refractory
ovari ancer: antitumor activity and toxicity
mod tion by liposomal encapsulation.
Second by degree and
first by hierarchy
Gabizon, A, Catane, R, Uziely, B, Kaufman, B,
Safra, T, Cohen, R, Martin, F, Huang, A, Barenholz, Y
Cancer research (Cancer Res), Vol. 54
(4): 987–92, 1994
Prolo d circulation time and enhanced
accum tion in malignant exudates of doxorubicin
enca ated in polyethylene-glycol coated liposomes.
Second by degree Uziely, B, Jeffers, S, Isacson, R, Kutsch, K, Wei-Tsao, D,
Yehoshua, Z, Libson, E, Muggia, F M, Gabizon, A
Journal of clinical oncology : official journal
of the American Society of Clinical Oncology
(J Clin Oncol), Vol. 13 (7): 1777–85, 1995
Lipos al doxorubicin: antitumor activity
and u ue toxicities during two
comp entary phase I studies.
Cluster 4
The first by degree
and first by hierarchy
Papahadjopoulos, D, Allen, T M, Gabizon, A,
Mayhew, E, Matthay, K, Huang, S K, Lee, K D,
Woodle, M C, Lasic, D D, Redemann, C
Proceedings of the National Academy of
Sciences of the United States of America (P
Natl Acad Sci Usa), Vol. 88 (24): 11460–4, 1991
Steric stabilized liposomes: improvements
in ph acokinetics and antitumor therapeutic efficacy.
Second by degree Vaage, J, Mayhew, E, Lasic, D, Martin, F International journal of cancer. (Int J Cancer),
Vol. 51 (6): 942–8, 1992
Thera of primary and metastatic mouse
mam y carcinomas with doxorubicin
enca ated in long circulating liposomes.
Cluster 3
The first by degree ElBayoumi, Tamer A, Torchilin, Vladimir P Clinical cancer research : an official journal
of the American Association for Cancer Research
(Clin Cancer Res), Vol. 15 (6): 1973–80, 2009
Tumo rgeted nanomedicines: enhanced antitumor
effica vivo of doxorubicin-loaded, long-circulating
liposo s modified with cancer-specific monoclonal antibody.
Second by degree Garde, Seema V, Forté, André J, Ge, Michael,
Lepekhin, Eugene A, Panchal, Chandra J,
Rabbani, Shafaat A, Wu, Jinzi J
Anti-cancer drugs (Anti-cancer Drug Des),
Vol. 18 (10): 1189–200, 2007
Bindi nd internalization of NGR-peptide-targeted
liposo l doxorubicin (TVT-DOX) in CD13-expressing
cells its antitumor effects.
The first by hierarchy Lee, R J, Low, P S Biochimica et biophysica acta (Biochim
Biophys Acta), Vol. 1233 (2): 134–44, 1995
Folat ediated tumor cell targeting of
liposo -entrapped doxorubicin in vitro.
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Table 2 Manuscripts with the highest degree of hierarchy within each of the clusters (Continued)
Cluster 5
The first by degree Kong, G, Anyarambhatla, G, Petros,
W P, Braun, R D, Colvin, O M, Needham,
D, Dewhirst, M W
Cancer research (Cancer Res),
Vol. 60 (24): 6950–7, 2000
Efficacy of liposomes and hyperthermia
in a human tumor xenograft model:
importance of triggered drug release.
Second by degree Needham, D, Anyarambhatla, G, Kong,
G, Dewhirst, M W
Cancer research (Cancer Res),
Vol. 60 (5): 1197–201, 2000
A new temperature-sensitive liposome for
use with mild hyperthermia: characterization
and testing in a human tumor xenograft model.
The first by hierarchy Mayhew, E G, Goldrosen, M H, Vaage, J, Rustum, Y M Journal of the National Cancer Institute
(J Natl Cancer I), Vol. 78 (4): 707–13, 1987
Effects of liposome-entrapped doxorubicin on liver
metastases of mouse colon carcinomas 26 and 38.
Cluster 6
The first by degree and
first by hierarchy
Northfelt, D W, Martin, F J, Working, P,
Volberding, P A, Russell, J, Newman, M,
Amantea, M A, Kaplan, L D
Journal of clinical pharmacology (J Clin
Pharmacol), Vol. 36 (1): 55–63, 1996
Doxorubicin encapsulated in liposomes containing
surface-bound polyethylene glycol: pharmacokinetics,
tumor localization, and safety in patients with
AIDS-related Kaposi's sarcoma.
Second by degree Hussein, Mohamad A, Wood, Laura, Hsi, Eric,
Srkalovic, Gordan, Karam, MaryAnn, Elson,
Paul, Bukowski, Ronald M
Cancer, Vol. 95 (10): 2160–8, 2002 A Phase II trial of pegylated liposomal doxorubicin,
vincristine, and reduced-dose dexamethasone combination
therapy in newly diagnosed multiple myeloma patients.
Cluster 7
The first by degree Batist, G, Ramakrishnan, G, Rao, C S, Chandrasekharan,
A, Gutheil, J, Guthrie, T, Shah, P, Khojasteh, A, Nair,
M K, Hoelzer, K, Tkaczuk, K, Park, Y C, Lee, L W .
Journal of clinical oncology: official journal
of the American Society of Clinical Oncology
(J Clin Oncol), Vol. 19 (5): 1444–54, 2001
Reduced cardiotoxicity and preserved antitumor
efficacy of liposome-encapsulated doxorubicin and
cyclophosphamide compared with conventional
doxorubicin and cyclophosphamide in a randomized,
multicenter trial of metastatic breast cancer.
Second by degree Harris, Lyndsay, Batist, Gerald, Belt, Robert, Rovira,
Douglas, Navari, Rudolph, Azarnia, Nozar, Welles,
Lauri, Winer, Eric, TLC D-99 Study Group .
Cancer, Vol. 94 (1): 25–36, 2002 Liposome-encapsulated doxorubicin compared
with conventional doxorubicin in a randomized
multicenter trial as first-line therapy of metastatic
breast carcinoma.
The first by hierarchy Balazsovits JA, Mayer LD, Bally MB, Cullis PR,
McDonell M, Ginsberg RS, Falk RE.
Cancer Chemother Pharmacol. 1989;23(2):81–6. Analysis of the effect of liposome encapsulation on
the vesicant properties, acute and cardiac toxicities,
and antitumor efficacy of doxorubicin.
Cluster 8
The first by degree and
first by hierarchy
Gordon AN, Fleagle JT, Guthrie D,
Parkin DE, Gore ME, Lacave AJ.
J Clin Oncol. 2001 Jul 15;19(14):3312–22. Recurrent epithelial ovarian carcinoma: a randomized
phase III study of pegylated liposomal doxorubicin
versus topotecan.
Second by degree Gordon, Alan N, Tonda, Margaret, Sun,
Steven, Rackoff, Wayne, Doxil Study
30–49 Investigators
Gynecologic oncology (Gynecol Oncol),
Vol. 95 (1): 1–8, 2004
Long-term survival advantage for women treated
with pegylated liposomal doxorubicin compared
with topotecan in a phase 3 randomized study of
recurrent and refractory epithelial ovarian cancer
Papers with the highest hierarchy are the common ancestors of the documents of each cluster. Effective degree is the number of weighted connections to other papers (give a idea about how much connected is a
paper to others highly connected documents of the network). Sometimes, the same paper has the highest hierarchy and most effective degree in a cluster.
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Figure 2 Network clusters which graphically summarizes the process of translation of knowledge and innovation on the liposomal
doxorubicin. Each node represents one of 8 clusters, the size depends on the number of documents that constitute them. The thickness of the
vertices is based on the total number of citations between each cluster, the vertex are labeled with these numbers.
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(USA), Hadassah Medical Organization and the University
of Alberta (Canada) which are institutions that participated
in the innovation of Doxil [14] are the main actors in the
cluster 2 (Table 3).Table 3 Main institution by their number of papers in
each cluster
Cluster 1
Hadassah Medical Organization, Israel. 6
British Columbia Cancer Agency, Canada. 5
Georgetown University, USA. 5
Hiroshima University, Japan. 3
University of British Columbia, Canada. 3
No information 14
Cluster 2
University of Southern California, USA. 5
Hadassah Medical Organization, Israel. 5
New York University, USA. 3
SEQUUS Pharmaceuticals, Inc., Menlo Park, USA. 3
University of Alberta, Canada. 3
Cluster 3
University of Alberta, Canada. 10
Hadassah Medical Organization, Israel. 4
Northeastern University, USA. 3
Peking University, China. 3
Cluster 4
Hadassah Medical Organization, Israel. 10
Roswell Park Cancer Institute, USA. 8
Cluster 5
Duke University, USA. 7
Harvard Medical School, USA. 6
University of California-San Francisco, USA 3
Cluster 6 Cleveland Clinic Foundation, USA. 3
Cluster 7 and 8 All institution have just one paper in
theses clusters
1
We only consider the corresponding address of the papers.Discussion
It is important to point out the meaning of our results.
It has been pointed out that a network of highly cited
papers is related to the paradigmatic structure of a specific
research field [34]. A literature network could be consid-
ered as a interconnected set of information routes, then
the topological position of a node, and therefore how
many times a paper is cited, matters with regard to how
much information it could actually transmit [35]. The
network model that we built from the 20% most cited
papers represents the core and the organizer of the
communication process of the liposomal doxorubicin
R&D. However, care must be taken not to confuse influ-
ence with veracity, validity or research quality: an influential
paper is not always the best, in terms of scientific quality
(whatever measure is used) [36,37].
Clustering methods are very useful to identify hidden
colleges, that is, informal networks of researchers that
read, cite, and interpret the reality of a problem in a very
similar way. In addition, clustering could serve to identify
paradigm shifts [38]. Clustering can map both informal
colleges arrangements and the paradigm shift, because the
former emerge from the latter. What we are seeing in our
maps is the emergence of Doxil as the paradigmatic model
of liposomal drugs (Figures 1 and 2). As mentioned earlier,
cluster 1 is the oldest and most undifferentiated group of
papers that corresponds with the invention stage. Cluster
4 and 2 represent the emergence of Doxil paradigm, and
their intense intercommunication is just the translational
process form basic to clinical research. The clusters 3 and
5 are bifurcations of the central paradigm, the former re-
lated to targeting and the latter related to hyperthemal
therapy. These topological bifurcations could be the novel
research context of a new generations of innovations like
MCC-46, and ThermoDox. MCC-46 is a inmunoliposomal
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Corp., which is in the first phase of clinical trials [12].
ThermoDox is a thermosensitive liposomal doxorubi-
cin developed by Celsion Corp. in phase III of clinical
studies [12].
The emergence of a paradigm implies the self-organizing
of a research community. Barenholz, one of the creators
of Doxil, takes account of the main actors and institutions
that led the innovation process of the first nanodrug [14].
What he says agrees with our results, in the sense that
documents with higher centrality and hierarchy of clusters
2 and 4 were conducted by an international collaboration
of Barenholz of the Hebrew University-Hadassah Medical
School in Jerusalem, Allen of the University of Alberta
in Canada, Gabizon of Hadassah University Hospital in
Jerusalem and Lasic of Liposome Technology Inc. in Menlo
Park, CA (see Figure 1, Tables 2 and 3).
Finally, it is important to keep in mind that convergence
of KT, paradigm emergence and innovation are deeply
affected by external regulatory processes such as the
FDA and patenting processes [15]. Cluster 2, for example,
is closely related to a family of patented inventions,
described by Barenholz [14], aimed to prolong liposomal
lifespan during plasma circulation. Probably the most
influent externality affecting the evolution of TI on
nanodrugs is the FDA and EMA (European Medician
Agency) approval process. From the beginning, Doxil
was designed to obtain the approval from the FDA and
the EMA [15]. Clinical trials are the main component of
the clinical field (clusters 4, 6, 7 and 8), and these must be
previously approved in USA by the FDA via the Investiga-
tional New Drug (IND) application [15]. Following the
clinical trials (phase I, II and III), it is mandatory to
summit the New Drug Application to the FDA for a
nanodrug enters the market [15]. An analysis of the
crosstalk between legal regulatory document, with patent
and literature networks for different countries could be
fundamental to reaching a deeper understanding on how
knowledge translation could be influenced by regulatory
processes and intellectual property systems.Conclusion
This exploratory research allows to simultaneously map
the convergence of KT, TI and paradigm emergence in the
first FDA approved nanodrug. In this regard, we have
developed a powerful tool for knowledge management in
nanomedicine. This work complements with the previous
research about KT in liposomes and metallic nanostru-
tures. This complementation provides us a relevant view
of the current stage of cancer nanotechnologies [17]. We
have a contrasting view of consolidated and recent types
of nanotechnologies, and we have a zoomed out general
perspective of cancer nanotechnologies contrasting with azoomed in view of the paradigmatic successful case of the
first FDA approved cancer nanotechnology.
In addition, this methodology has the potential to
become a useful evaluating tool for KT. For example,
Rajan et al. have pointed out there are two classes of KT
models: the T models and the process models [39]. The
firsts are focus in describe “phases/components for trans-
lational research in different blocks”. While, the second
type of models describe the process of KT. Rajan et al. state
that T models are not appropriated for “evaluating and
improving the the performance of translational research”.
Our research integrates both types of models. This method-
ology can identify stages of the KT and determinate how
strongly- and in a near future how effective and efficient-
these stages are interacting with each other.
Much remains to be done; for example, it could be
interesting to study how the structure of knowledge is
affected when a drug is not approved, how the crosstalk
between regulation and research is organized, or which
institutions lead the process. These areas of research are
currently under way in our group.
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